Real-world Study of Trilaciclib to Prevent Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Cancer

What this Trial Is About

Researchers are evaluating the use of trilaciclib, a drug designed to protect bone marrow, in patients with esophageal squamous cell carcinoma ESCC who are undergoing chemoradiotherapy. Chemoradiotherapy-induced myelosuppression CIM is a common and serious side effect that can cause delays or changes in cancer treatment. This study explores trilaciclibs safety and effectiveness in preventing myelosuppression during treatment, a first for this type of cancer. The study compares two groups of patients one receiving trilaciclib combined with chemoradiotherapy and a control group receiving only chemoradiotherapy. Trilaciclib is given before each chemotherapy session. Researchers collected clinical data from patients treated at Jiangsu Provincial Peoples Hospital and used statistical methods to balance characteristics between the groups, then compared rates of bone marrow suppression and other adverse events. Participants are monitored for the incidence of severe neutropenia and other side effects during treatment and up to one year afterward. Data collection includes clinical assessments and the recording of adverse events. The study aims to provide real-world evidence on whether trilaciclib can reduce myelosuppression related to chemoradiotherapy in ESCC patients, helping to maintain treatment schedules and improve patient outcomes.

Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma